Emcure Pharmaceuticals Valuation
Is 544210 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
2/6Valuation Score 2/6
Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of 544210 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: 544210 (₹1313.6) is trading above our estimate of fair value (₹733.8)
Significantly Below Fair Value: 544210 is trading above our estimate of fair value.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 544210?
Key metric: As 544210 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.
| What is 544210's PE Ratio? | |
|---|---|
| PE Ratio | 43.8x |
| Earnings | ₹5.67b |
| Market Cap | ₹242.71b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 3.5x |
| Enterprise Value/EBITDA | 20x |
| PEG Ratio | 1.7x |
Price to Earnings Ratio vs Peers
How does 544210's PE Ratio compare to its peers?
| Company | Forward PE | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 76.5x | ||
LAURUSLABS Laurus Labs | 210.8x | 55.6% | ₹263.7b |
506943 J. B. Chemicals & Pharmaceuticals | 44.1x | 19.4% | ₹266.4b |
NATCOPHARM NATCO Pharma | 12.5x | -20.4% | ₹246.2b |
PFIZER Pfizer | 38.7x | 12.9% | ₹234.7b |
544210 Emcure Pharmaceuticals | 43.8x | 25.3% | ₹242.7b |
Price-To-Earnings vs Peers: 544210 is good value based on its Price-To-Earnings Ratio (43.8x) compared to the peer average (76.5x).
Price to Earnings Ratio vs Industry
How does 544210's PE Ratio compare vs other companies in the IN Pharmaceuticals Industry?
| 2 Companies | Price / Earnings | Estimated Growth | Market Cap |
|---|---|---|---|
INDSWFTLAB Ind-Swift Laboratories | 1.6x | n/a | US$71.82m |
524652 Ind-Swift | 2x | n/a | US$13.29m |
| 2 Companies | Estimated Growth | Market Cap |
|---|
Price-To-Earnings vs Industry: 544210 is expensive based on its Price-To-Earnings Ratio (43.8x) compared to the Indian Pharmaceuticals industry average (31.6x).
Price to Earnings Ratio vs Fair Ratio
What is 544210's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PE Ratio | 43.8x |
| Fair PE Ratio | n/a |
Price-To-Earnings vs Fair Ratio: Insufficient data to calculate 544210's Price-To-Earnings Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
| Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
|---|---|---|---|---|---|---|---|
| Current | ₹1,313.60 | ₹1,640.00 +24.8% | 2.6% | ₹1,680.00 | ₹1,580.00 | n/a | 3 |
| Nov ’25 | ₹1,442.00 | ₹1,575.00 +9.2% | 4.9% | ₹1,655.00 | ₹1,470.00 | n/a | 3 |
| Oct ’25 | ₹1,493.75 | ₹1,575.00 +5.4% | 4.9% | ₹1,655.00 | ₹1,470.00 | n/a | 3 |
| Sep ’25 | ₹1,399.35 | ₹1,535.00 +9.7% | 4.2% | ₹1,600.00 | ₹1,470.00 | n/a | 2 |
Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.
Discover undervalued companies
Mercury Laboratories
₹1.1b
Develops, manufactures, markets, distributes, and sells pharmaceutical drugs, medicines, and formulations for mother and child healthcare in India and internationally.
538964
₹928.00
7D
-1.7%
1Y
15.6%
Bal Pharma
₹2.2b
Manufactures and markets pharmaceutical formulations and active pharmaceutical ingredients (APIs) in India and internationally.
BALPHARMA
₹137.15
7D
13.8%
1Y
30.6%
Caplin Point Laboratories
₹147.7b
Engages in the development, production, marketing, and export of generic pharmaceutical formulations and branded products in India.
CAPLIPOINT
₹1,963.75
7D
0.6%
1Y
59.7%